Abstract
The time is now right for randomized trials of MDR-TB, say the authors, as the expansion of MDR-TB programs provides the setting in which trials can be implemented.
MeSH terms
-
Antitubercular Agents / therapeutic use*
-
Extensively Drug-Resistant Tuberculosis / drug therapy*
-
Extensively Drug-Resistant Tuberculosis / microbiology
-
Fluoroquinolones / therapeutic use
-
Humans
-
Mycobacterium tuberculosis
-
Randomized Controlled Trials as Topic
-
Tuberculosis, Multidrug-Resistant / drug therapy*
-
Tuberculosis, Multidrug-Resistant / microbiology
Substances
-
Antitubercular Agents
-
Fluoroquinolones